Pasireotide
Lua error in Module:Infobox at line 314: malformed pattern (missing ']').
Pasireotide (SOM230, trade name Signifor[2]) is an orphan drug approved in the U.S. and Europe for the treatment of Cushing's disease and acromegaly in patients who fail or are ineligible for surgical therapy.[3][4] It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.
Pasireotide was approved for Cushing's disease by the EMEA in October 2009[5] and by the FDA in December 2012.[6]
Pasireotide LAR was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMEA one month earlier.[7]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." /><templatestyles src="Asbox/styles.css"></templatestyles>
 |
This hormonal preparation article is a stub. You can help Wikipedia by expanding it. |
- ↑ Pasireotide | C58H66N10O9 - PubChem http://pubchem.ncbi.nlm.nih.gov/compound/Pasireotide
- ↑ Signifor® (pasireotide) Official Website for healthcare professionals outside the US http://www.signifor.com/
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ EMEA Approval for Pasireotide
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Tucker, Miriam E. FDA Approves Pasireotide for Treating Acromegaly, Medscape, December 17, 2014, Retrieved 2015-08-21
